Paion: study shows effectiveness of Desmoteplase in hemorrhagic stroke

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Paion said results from a large animal model study of hemorrhagic stroke showed that the company's clot-busting drug Desmoteplase may aid in treating the life-threatening condition with a 50% mortality rate.

Desmoteplase showed less brain edema and less inflammation compared to rt-PA.

"These interesting results support previous findings regarding Desmoteplase's unique properties with regard to the central nervous system," chief medical officer Mariola Soehngen said in the release.

The study results were released at the 18th International Congress on Fibrinolysis and Proteolysis in San Diego.

Paion is a biopharmaceutical company based in Aachen, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.